Recent research showed that glutamine metabolism has distinct roles in promoting Th17 cells and inhibiting Th1 cells and that GLS inhibition can reverse such effects in inflammatory diseases.[18] Since JHU083 is a glutamine metabolism inhibitor, our results demonstrated similar findings in an EGFR‐driven lung cancer model. Here, GLS is linked to lung carcinoma.